List of Radiopharmaceuticals/Radiotherapies Companies in China - 6

Developer of targeted radionuclide therapies used to treat cancer. The company develops radioactive drugs and other nuclear therapies.

Bivision is a China-based biopharmaceutical company that develops visually targeted radionuclide therapies for the treatment of cancer across the globe.

C Ray Therapeutics, established in 2021 and headquartered in Chengdu Medical City, is incubated by internationally renowned investment institutions 6 Dimensions Capital. Since its establishment, C Ray has been dedicated to the field of radiopharmaceuticals, aiming for world-class standards. Within just over three years, the company has achieved a series of landmark accomplishments: > Construction of a nearly 30,000 square meter R&D and production base for radiopharmaceuticals. > Obtaining the first Class A Radiation Safety License for an innovative radiopharmaceutical enterprise. > Establishing a leading platform with advanced global equipment, cutting-edge technology innovation, and comprehensive functional support in the field of radiopharmaceuticals.

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

Mido (Nanjing) Biotechnology Co., Ltd. is the first molecular imaging pharmaceutical research and development outsourcing (MI-CRO) company in China. The company leverages the world’s most advanced radiolabeling and in vivo molecular imaging technologies to provide domestic and international clients with comprehensive solutions and outsourced technical services for new drug R&D, including drug screening, biodistribution, pharmacokinetic research, and pharmacodynamic evaluation. Its business spans translational research from nude mice, rats, and monkeys to humans, focusing on major diseases such as cancer, coronary heart disease, Alzheimer’s disease, Parkinson’s disease, epilepsy, rheumatism, and diabetes, as well as cutting-edge fields involving receptors, genes, and stem cells. It explores disease mechanisms, develops diagnostic and therapeutic drugs, and evaluates therapeutic outcomes. PET molecular imaging offers unique advantages—such as in vivo imaging, dynamic quantification, self-control, and continuous observation—that significantly shorten the drug development cycle, reduce the risk of failure, and accelerate the introduction of new drugs to the market. 米度（南京）生物技术有限公司是国内首家分子影像医药研发外包（MI-CRO）企业。公司利用世界先进的放射标记示踪（Radiolabeling）和活体分子显像（Molecular imaging）技术为海内外客户提供药物筛选、生物分布、药代动力学研究、药效学评价等新药研发整体解决方案和外包技术服务，业务贯穿从裸（小）鼠、大鼠、猴子到人体的转化研究，重点针对肿瘤、冠心病、老年痴呆、帕金森、癫痫、风湿免疫、糖尿病等重大疾病以及受体、基因、干细胞等前沿研究领域，探寻疾病机理、开发诊疗药物、评价治疗效果。PET 分子影像具有活体显像、动态定量、自身对照、连续观察等突出优点，大大缩短药物研发周期、降低失败风险、加快新药上市。

SmartNuclide Biopharma is a biopharmaceutical company that focuses on discovering and developing innovative biologics used in nuclear medicine, with a world-leading research and development technology platform for domain antibody-radiopharmaceuticals.